Pfizer, Mylan Can't Quickly Appeal EpiPen RICO Class Cert.

By Hannah Albarazi · May 26, 2020, 11:10 PM EDT

EpiPen manufacturer Pfizer and distributor Mylan cannot immediately appeal a Kansas federal judge's certification of a nationwide class under the Racketeer Influenced and Corrupt Organizations Act in multidistrict litigation over the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Hannah

August 13, 2024
Are 'Public Advantage' Laws Driving Up Healthcare Costs?
July 30, 2024
5th Circ. Ruling Places FCC Rural Telehealth Funding In Peril
July 29, 2024
Boehringer Appeals HHS Win In Medicare Drug Price Suit
July 09, 2024
With Chevron's End, LGBTQ+ Healthcare Regs Face New Risk
June 18, 2024
High Court Petition Asks Justices: What's A 'Willful' Kickback?
June 04, 2024
Texas Justices Fuel Confusion Over Abortion Ban Exceptions
May 02, 2024
Feds Call Out Gilead's Efforts To Revise HIV Drug IP Judgment
April 05, 2024
Ind. Can't Undo Abortion Law Injunction In Jewish Org's Case
March 29, 2024
Calif. Justices Rule Living Wills Not A Path To Arbitration
March 05, 2024
Gibson Dunn AI Leader On Weathering The AI Policy Blizzard